Health Care·Pharmaceuticals·$4.0B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.73 | N/A | -3.84% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.73 | N/A | -3.84% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management expressed cautious optimism about the company's clinical developments. However, they did not provide specific guidance for future performance.
Management highlighted ongoing progress in clinical trials.
They emphasized commitment to advancing their pipeline.
No specific guidance was provided for future quarters.
Crinetics Pharmaceuticals reported a loss per share that was slightly worse than expected, but the stock rose by 1.01%. This increase may reflect investor confidence in the company's ongoing clinical trials and future potential, despite the lack of revenue data and specific guidance. The market seems to be focusing on long-term growth prospects rather than short-term earnings.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
VERISK ANALYTICS INC A
Nov 2, 2021